Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis

dc.contributor.authorOzgocmen, Salih
dc.contributor.authorKaya, Huseyin
dc.contributor.authorFadillioglu, Ersin
dc.contributor.authorYilmaz, Zumrut
dc.date.accessioned2026-08-12T17:39:49Z
dc.date.issued2007
dc.departmentFırat Üniversitesi
dc.description.abstractBackground. The aims of this study were to compare erythrocyte antioxidant enzyme activities, lipid peroxidation, and nitric oxide levels (NO) in women with postmenopausal osteoporosis (PMO) and non-porotic postmenopausal healthy controls and to assess the relationship between bone mineral density and these oxidant/antioxidant parameters. Additionally, in vivo effects of three different anti-osteoporotic drugs, calcitonin, risedronate and raloxifene, on the erythrocyte oxidant-antioxidant status in women with PMO were also assessed. Methods. Postmenopausal women aged 40-65 years and without previous diagnosis or treatment for osteoporosis and independent in activities of daily living were included. Bone mineral density was measured at the lumbar spine and proximal femur using DXA. Erythrocyte enzyme activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), and lipid peroxidation end-product malondialdehyde (MDA) and nitrite/nitrate levels, by product of NO, were assessed. Fifty-nine women with PMO were included (mean age 56.7 years), 44 completed course of therapy and were analyzed. Twenty-two non-porotic healthy women (mean age 55.8 years) were included as controls. Results. Patients had significantly lower CAT and GSH-Px enzyme activity and higher levels of MDA and NO than non-porotic healthy controls. Proximal femur BMD measurements significantly correlated with NO levels. QUALEFFO scores improved in different levels with these short-term treatments. In all treatment groups, erythrocyte MDA levels significantly decreased; moreover, risedronate reduced NO levels and raloxifene enhanced CAT enzyme activity. Conclusions. Oxidative stress plays an important role in the pathogenesis of PMO. Studied drugs had ultimate effects on reducing lipid peroxidation. Raloxifene also had potent effects in the enhancement of antioxidant defense system. (c) 2007 IMSS. Published by Elsevier Inc.
dc.identifier.doi10.1016/j.arcmed.2006.09.010
dc.identifier.endpage205
dc.identifier.issn0188-4409
dc.identifier.issn1873-5487
dc.identifier.issue2
dc.identifier.orcid0000-0002-4860-452X
dc.identifier.pmid17227729
dc.identifier.startpage196
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2006.09.010
dc.identifier.urihttps://hdl.handle.net/11508/58972
dc.identifier.volume38
dc.identifier.wosWOS:000243949800007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofArchives of Medical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectpostmenopausal osteoporosis
dc.subjectcalcitonin
dc.subjectrisedronate
dc.subjectraloxifene
dc.subjectantioxidant enzyme
dc.subjectnitric oxide
dc.titleEffects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis
dc.typeArticle

Dosyalar